Sinem Nihal Esatoglu
Overview
Explore the profile of Sinem Nihal Esatoglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
420
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karakoc A, Ozguler Y, Ozdede A, Ferhatoglu Z, Yildiz K, Kutlubay Z, et al.
Semin Arthritis Rheum
. 2025 Feb;
71:152643.
PMID: 39929007
Introduction: Post-thrombotic syndrome (PTS) and stasis ulcers are late complications of deep vein thrombosis (DVT) in Behçet's syndrome (BS). We aimed to determine the clinical and histopathological characteristics, treatment modalities,...
2.
Esatoglu S, Ozdede A, Ozguler Y, Tascilar K, Yazici H
Trials
. 2025 Jan;
26(1):28.
PMID: 39863858
Background: It was our impression that safety outcome trials were getting more frequent, raising ethical issues mainly related to patient autonomy. We and others had also proposed this autonomy would...
3.
Esatoglu S, Sonmez O, Ucar D, Kaymaz E, Ozguler Y, Ugurlu S, et al.
Rheumatology (Oxford)
. 2024 Aug;
PMID: 39110537
Objectives: Treatment response may be variable across organ manifestations of Behçet syndrome (BS). We aimed to determine the frequency of de novo manifestations during adalimumab treatment. Methods: We conducted a...
4.
Ucar D, Bircan B, Rustamli N, Batu Oto B, Hamuryudan V, Hatemi G, et al.
Ocul Immunol Inflamm
. 2024 Jul;
33(2):243-249.
PMID: 39079032
Purpose: The prognostic importance of vitreous cells (VC) in patients with Behçet syndrome (BS) is unknown. We aimed to determine the frequency of developing posterior uveitis (PU) and any additional...
5.
Ozdede A, Esatoglu S, Durmaz E, Karakoc A, Ogun H, Hatemi G, et al.
Clin Exp Rheumatol
. 2024 Jul;
42(10):2057-2064.
PMID: 38976306
Objectives: Tocilizumab has been increasingly reported as an alternative therapeutic agent in the management of Behçet's syndrome (BS) and it has been mostly tried in BS patients with neurological and...
6.
Ozyazgan Y, Ucar D, Batu Oto B, Esatoglu S, Ozguler Y, Hatemi G, et al.
Ocul Immunol Inflamm
. 2024 May;
32(10):2332-2338.
PMID: 38768092
Introduction/objective: There is currently no tool available to assess the severity of damage in uveitis due to Behçet's syndrome (BS). In this preliminary study, we developed a new grading system...
7.
Kimyon U, Gozen E, Karaman E, Gunay E, Esatoglu S, Atas A, et al.
Clin Exp Rheumatol
. 2024 Mar;
42(4):872-878.
PMID: 38489315
Objectives: Neurosensory hearing loss is well-documented in chronic autoimmune conditions such as systemic lupus erythematosus (SLE). However, the literature lacks data on the prevalence and characteristics of hearing impairment in...
8.
Erdogan M, Esatoglu S, Kilickiran Avci B, Hatemi G
Intern Emerg Med
. 2024 Feb;
19(3):731-743.
PMID: 38378970
The evidence for the treatment of connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) mostly depends on subgroup or post hoc analysis of randomized controlled trials (RCTs). Thus, we performed a...
9.
Onen M, Everest E, Demirci T, Koprulu Sen P, Kiziltepe Kisakesen E, Ozguler Y, et al.
Clin Exp Rheumatol
. 2024 Jan;
42(10):2014-2020.
PMID: 38293994
Objectives: The HLA-B51 locus has the strongest association with Behçet's syndrome (BS). The presence of a CpG island in the HLA-B gene led us to examine the role of epigenetic...
10.
Esatoglu S, Ozguler Y, Hatemi G
Curr Rheumatol Rep
. 2023 Nov;
26(1):1-11.
PMID: 37995045
Purpose Of Review: We aimed to highlight disease-related and treatment-related complications of Behçet syndrome (BS) based on previous and recent studies and our own experience. Recent Findings: The Behçet's Disease...